Navigation Links
Selexis SA to Present at Biotech Showcase 2012
Date:1/5/2012

GENEVA, Switzerland, Jan. 5, 2012  /PRNewswire/ -- Selexis SA announced today the Company's president and CEO, Igor Fisch, Ph.D., will present at the Biotech Showcase 2012 Conference held in conjunction with the annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Dr. Fisch will present, "Translating Drug Discovery into Clinical Success: A Growth Investment" to prospective investors and corporate partners on Monday, January 9 at 11:00 AM in the Stockton Room at the Park 55 Wyndham.   The presentation will cover existing commercial offerings, the expansion of the SUREtechnology Platform™ and new market opportunities in drug discovery, next generation biologics and difficult to express proteins. 

"Biotech Showcase is an ideal opportunity for us to highlight our innovations and our applications of the SUREtechnology Platform™ supporting the biopharmaceutical industry's drug discovery efforts," said Dr. Fisch.  "Using Selexis' platform from discovery through manufacturing helps improve chances of clinical success while reducing development timelines and costs."

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins.  The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.  The Company anticipates three products manufactured from cell lines using the Selexis SUREtechnology Platform™ to be launched in 2012.

For more information, visit http://www.selexis.com

Selexis SA
Robert Meister
robert.meister@selexis.com
(602) 953-1716


'/>"/>
SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Selexis Launches Biosimilar Cell Line Development Program
2. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
3. Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
4. Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
5. Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC
6. Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011
7. CSL Limited Signs Commercial License Agreement with Selexis SA
8. InterMune to Present at Canaccord Adams Conference
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
10. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
11. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):